Swk Hldgs Corp Stock Price, News & Analysis

Silicon Labs (NASDAQ: SLAB) has finalized the sale of its Infrastructure & Automotive business to Skyworks Solutions (NASDAQ: SWKH) for $2.75 billion in cash. This divestiture marks a pivotal shift, allowing Silicon Labs to focus solely on secure, intelligent wireless connectivity, a critical area in the growing global IoT market. The company plans to return approximately $2.0 billion to shareholders post-transaction through special dividends and share buybacks, with net proceeds estimated at $2.3 billion after costs.

SWK Holdings Corporation (Nasdaq: SWKH) announced advancements during the first half of 2021 across its portfolio. The company emphasized a strong recovery in life sciences, attributing growth to its unique financing structures for small and mid-sized firms. Highlights include a $10 million milestone from Cara Therapeutics for Oral KORSUVA development and ongoing progress at Enteris BioPharma. Notable transactions include a $9.5 million financing with Trio Healthcare and a $5 million royalty deal with Ideal Implant. SWK recorded a 1.5x multiple on invested capital from borrower repayments.

SWK Holdings Corporation (Nasdaq: SWKH) has authorized a stock repurchase program of up to $5.0 million, effective until March 15, 2022. This initiative, executed through a 10b5-1 trading plan, aims to enhance shareholder value amidst ongoing strategic reviews. CEO Winston Black stated that the buyback represents an optimal use of capital during this period. The program could start as early as July 15, 2021, depending on market conditions and trading constraints.

Enteris BioPharma, a biotechnology company and a subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), is hosting a webinar titled "Key Considerations for HPAPI Oral Drug Product Development" on June 29, 2021, at 1 p.m. ET. The event will feature experts Josh Stephens and Angelo Consalvo, discussing trends in outsourcing the manufacture of solid oral drugs with high potency active pharmaceutical ingredients (HPAPI). The webinar aims to provide insights into selecting a contract development and manufacturing organization (CDMO) and address the rising demand in this sector.

SWK Holdings Corporation (Nasdaq: SWKH) announced that its subsidiary, Enteris BioPharma, received a $10 million milestone payment from Cara Therapeutics (Nasdaq: CARA) related to the licensing of Peptelligence technology for Oral KORSUVA. Enteris will retain $3.9 million from this payment. This payment follows the completion of an End-of-Phase 2 Meeting with the FDA regarding Oral KORSUVA for chronic kidney disease. Enteris has previously received milestone payments totaling $5 million and is eligible for more as development milestones are achieved.

Enteris BioPharma, a subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), will participate in the BIO Digital 2021 conference from June 14-18, 2021. The company plans to engage in virtual meetings with pharmaceutical leaders to discuss its innovative technologies, Peptelligence® and ProPerma™, which enable oral delivery of various compounds. Enteris recently launched contract development and manufacturing operations and expanded its facilities. CEO Rajiv Khosla emphasized the potential of these technologies to enhance partnerships and meet significant market needs.

The Board of Directors of SWK Holdings Corporation (Nasdaq: SWKH) and its controlling stockholder, Carlson Capital, L.P., have announced the formation of a Strategic Review Committee to explore options aimed at maximizing shareholder value. The committee, chaired by Marcus Pennington of Carlson, will include existing board members and commence work immediately. Carlson has withdrawn its earlier acquisition proposal for the company's loan and royalty assets. No assurance of a transaction is made, and there is no set timetable for the committee's exploration.

SWK Holdings Corporation (SWKH) reported financial results for Q1 2021, achieving total revenue of $9.4 million, up from $7.3 million YoY, driven by finance receivables interest income. GAAP net income reached $3.4 million ($0.26 per share) compared to a loss of $4.7 million in Q1 2020. Notable increases include a 39% rise in adjusted non-GAAP net income to $4.7 million. The company also expanded its subsidiary, Enteris BioPharma, enhancing production capabilities. SWK closed $14 million in financings and formed a strategic review committee to explore options for maximizing shareholder value.

Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), has expanded its Boonton, NJ manufacturing facility by 32,000 square feet, incorporating 6,000 square feet of cleanroom space. This expansion includes a dedicated area for handling high potency active pharmaceutical ingredients (HPAPI) and allows for the development and manufacturing of solid oral doses, including those difficult to formulate. Enteris aims to enhance its contract development and manufacturing organization (CDMO) services and deepen existing partnerships, thereby positioning itself for future growth opportunities.